{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:33:27Z","timestamp":1791506007585,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s10067-024-07266-y","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T14:26:01Z","timestamp":1734359161000},"page":"247-256","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Effectiveness and safety of Belimumab and Telitacicept in systemic lupus erythematosus: a real-world, retrospective, observational study"],"prefix":"10.1007","volume":"44","author":[{"given":"Hui-Zhi","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Long","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-feng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-dong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo-sheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-mei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changhao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0828-1583","authenticated-orcid":false,"given":"Zhu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"issue":"9","key":"7266_CR1","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","volume":"17","author":"MRW Barber","year":"2021","unstructured":"Barber MRW, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow NY et al (2021) Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol 17(9):515\u2013532. https:\/\/doi.org\/10.1038\/s41584-021-00668-1","journal-title":"Nat Rev Rheumatol"},{"issue":"10188","key":"7266_CR2","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/S0140-6736(19)30546-X","volume":"393","author":"T Dorner","year":"2019","unstructured":"Dorner T, Furie R (2019) Novel paradigms in systemic lupus erythematosus. Lancet 393(10188):2344\u20132358. https:\/\/doi.org\/10.1016\/S0140-6736(19)30546-X","journal-title":"Lancet"},{"issue":"1","key":"7266_CR3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41584-018-0133-2","volume":"15","author":"M Gatto","year":"2019","unstructured":"Gatto M, Zen M, Iaccarino L, Doria A (2019) New therapeutic strategies in systemic lupus erythematosus management. Nat Rev Rheumatol 15(1):30\u201348. https:\/\/doi.org\/10.1038\/s41584-018-0133-2","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"7266_CR4","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1136\/ard-2022-223741","volume":"82","author":"MK Crow","year":"2023","unstructured":"Crow MK (2023) Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets. Ann Rheum Dis 82(8):999\u20131014. https:\/\/doi.org\/10.1136\/ard-2022-223741","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 6","key":"7266_CR5","doi-asserted-by":"publisher","first-page":"vi21","DOI":"10.1093\/rheumatology\/keab498","volume":"60","author":"ASMWP Tsang","year":"2021","unstructured":"Tsang ASMWP, Bultink IEM (2021) New developments in systemic lupus erythematosus. Rheumatology (Oxford) 60(Suppl 6):vi21\u2013vi8. https:\/\/doi.org\/10.1093\/rheumatology\/keab498","journal-title":"Rheumatology (Oxford)"},{"key":"7266_CR6","doi-asserted-by":"publisher","first-page":"102873","DOI":"10.1016\/j.jaut.2022.102873","volume":"132","author":"L Arbitman","year":"2022","unstructured":"Arbitman L, Furie R, Vashistha H (2022) B cell-targeted therapies in systemic lupus erythematosus. J Autoimmun 132:102873. https:\/\/doi.org\/10.1016\/j.jaut.2022.102873","journal-title":"J Autoimmun"},{"issue":"3","key":"7266_CR7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","volume":"20","author":"DSW Lee","year":"2021","unstructured":"Lee DSW, Rojas OL, Gommerman JL (2021) B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov 20(3):179\u2013199. https:\/\/doi.org\/10.1038\/s41573-020-00092-2","journal-title":"Nat Rev Drug Discov"},{"key":"7266_CR8","doi-asserted-by":"publisher","first-page":"102861","DOI":"10.1016\/j.jaut.2022.102861","volume":"132","author":"H Lou","year":"2022","unstructured":"Lou H, Ling GS, Cao X (2022) Autoantibodies in systemic lupus erythematosus: from immunopathology to therapeutic target. J Autoimmun 132:102861. https:\/\/doi.org\/10.1016\/j.jaut.2022.102861","journal-title":"J Autoimmun"},{"issue":"1","key":"7266_CR9","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC et al (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62(1):222\u2013233. https:\/\/doi.org\/10.1002\/art.27233","journal-title":"Arthritis Rheum"},{"issue":"3","key":"7266_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40265-018-0872-z","volume":"78","author":"HA Blair","year":"2018","unstructured":"Blair HA, Duggan ST (2018) Belimumab: a review in systemic lupus erythematosus. Drugs 78(3):355\u2013366. https:\/\/doi.org\/10.1007\/s40265-018-0872-z","journal-title":"Drugs"},{"issue":"12","key":"7266_CR11","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G et al (2020) Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 383(12):1117\u20131128. https:\/\/doi.org\/10.1056\/NEJMoa2001180","journal-title":"N Engl J Med"},{"issue":"9767","key":"7266_CR12","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377(9767):721\u2013731. https:\/\/doi.org\/10.1016\/S0140-6736(10)61354-2","journal-title":"Lancet"},{"issue":"14","key":"7266_CR13","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s40265-021-01591-1","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S (2021) Telitacicept: first approval. Drugs 81(14):1671\u20131675. https:\/\/doi.org\/10.1007\/s40265-021-01591-1","journal-title":"Drugs"},{"issue":"1","key":"7266_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1358\/dot.2022.58.1.3352743","volume":"58","author":"Y Fan","year":"2022","unstructured":"Fan Y, Gao D, Zhang Z (2022) Telitacicept, a novel humanized, recombinant TACI-Fc fusion protein, for the treatment of systemic lupus erythematosus. Drugs Today (Barc) 58(1):23\u201332. https:\/\/doi.org\/10.1358\/dot.2022.58.1.3352743","journal-title":"Drugs Today (Barc)"},{"issue":"6","key":"7266_CR15","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1080\/08923973.2021.1973493","volume":"43","author":"F Shi","year":"2021","unstructured":"Shi F, Xue R, Zhou X, Shen P, Wang S, Yang Y (2021) Telitacicept as a BLyS\/APRIL dual inhibitor for autoimmune disease. Immunopharmacol Immunotoxicol 43(6):666\u2013673. https:\/\/doi.org\/10.1080\/08923973.2021.1973493","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"7266_CR16","doi-asserted-by":"publisher","first-page":"1074044","DOI":"10.3389\/fimmu.2022.1074044","volume":"13","author":"M Nikoloudaki","year":"2022","unstructured":"Nikoloudaki M, Nikolopoulos D, Koutsoviti S, Flouri I, Kapsala N, Repa A et al (2022) Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: a real-life, multicentre observational study. Front Immunol 13:1074044. https:\/\/doi.org\/10.3389\/fimmu.2022.1074044","journal-title":"Front Immunol"},{"issue":"1","key":"7266_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/09612033221141253","volume":"32","author":"R Chen","year":"2023","unstructured":"Chen R, Fu R, Lin Z, Huang C, Huang W (2023) The efficacy and safety of telitacicept for the treatment of systemic lupus erythematosus: a real life observational study. Lupus 32(1):94\u2013100. https:\/\/doi.org\/10.1177\/09612033221141253","journal-title":"Lupus"},{"key":"7266_CR18","doi-asserted-by":"publisher","unstructured":"Jin HZ, Li YJ, Wang X, Li Z, Ma B, Niu L et al (2023) Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study. Lupus Sci Med 10(2). https:\/\/doi.org\/10.1136\/lupus-2023-001074","DOI":"10.1136\/lupus-2023-001074"},{"key":"7266_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224854","author":"D Wu","year":"2023","unstructured":"Wu D, Li J, Xu D, Merrill JT, van Vollenhoven RF, Liu Y et al (2023) Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/ard-2023-224854","journal-title":"Ann Rheum Dis"},{"key":"7266_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1196\/annals.1313.004","volume":"1050","author":"JO Pers","year":"2005","unstructured":"Pers JO, Daridon C, Devauchelle V, Jousse S, Saraux A, Jamin C et al (2005) BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 1050:34\u201339. https:\/\/doi.org\/10.1196\/annals.1313.004","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"7266_CR21","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1002\/art.21138","volume":"52","author":"W Stohl","year":"2005","unstructured":"Stohl W, Xu D, Kim KS, Koss MN, Jorgensen TN, Deocharan B et al (2005) BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus. Arthritis Rheum 52(7):2080\u20132091. https:\/\/doi.org\/10.1002\/art.21138","journal-title":"Arthritis Rheum"},{"issue":"1","key":"7266_CR22","doi-asserted-by":"publisher","first-page":"e000063","DOI":"10.1136\/lupus-2014-000063","volume":"2","author":"E Zollars","year":"2015","unstructured":"Zollars E, Bienkowska J, Czerkowicz J, Allaire N, Ranger AM, Magder L et al (2015) BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year. Lupus Sci Med 2(1):e000063. https:\/\/doi.org\/10.1136\/lupus-2014-000063","journal-title":"Lupus Sci Med"},{"issue":"3","key":"7266_CR23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC (2011) An Introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 46(3):399\u2013424. https:\/\/doi.org\/10.1080\/00273171.2011.568786","journal-title":"Multivariate Behav Res"},{"issue":"9","key":"7266_CR24","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725. https:\/\/doi.org\/10.1002\/art.1780400928","journal-title":"Arthritis Rheum"},{"issue":"4","key":"7266_CR25","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s10067-021-05989-w","volume":"41","author":"CE Insfran","year":"2022","unstructured":"Insfran CE, Aikawa NE, Pasoto SG, Filho DMN, Formiga FFC, Pitta AC et al (2022) 2019-EULAR\/ACR classification criteria domains at diagnosis: predictive factors of long-term damage in systemic lupus erythematosus. Clin Rheumatol 41(4):1079\u20131085. https:\/\/doi.org\/10.1007\/s10067-021-05989-w","journal-title":"Clin Rheumatol"},{"issue":"5","key":"7266_CR26","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.autrev.2011.06.011","volume":"11","author":"KM Luijten","year":"2012","unstructured":"Luijten KM, Tekstra J, Bijlsma JW, Bijl M (2012) The Systemic Lupus Erythematosus Responder Index (SRI); a new SLE disease activity assessment. Autoimmun Rev 11(5):326\u2013329. https:\/\/doi.org\/10.1016\/j.autrev.2011.06.011","journal-title":"Autoimmun Rev"},{"issue":"9","key":"7266_CR27","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","volume":"75","author":"K Franklyn","year":"2016","unstructured":"Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L et al (2016) Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 75(9):1615\u20131621. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207726","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"7266_CR28","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/BOR.0000000000000736","volume":"32","author":"G Murphy","year":"2020","unstructured":"Murphy G, Isenberg DA (2020) Biologic therapies for systemic lupus erythematosus: where are we now? Curr Opin Rheumatol 32(6):597\u2013608. https:\/\/doi.org\/10.1097\/BOR.0000000000000736","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"7266_CR29","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/1756-185X.12490","volume":"18","author":"CB Bernal","year":"2015","unstructured":"Bernal CB, Zamora LD, Navarra SV (2015) Biologic therapies in systemic lupus erythematosus. Int J Rheum Dis 18(2):146\u2013153. https:\/\/doi.org\/10.1111\/1756-185X.12490","journal-title":"Int J Rheum Dis"},{"issue":"5","key":"7266_CR30","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1177\/0961203317739132","volume":"27","author":"JP Suso","year":"2018","unstructured":"Suso JP, Posso-Osorio I, Jimenez CA, Naranjo-Escobar J, Ospina FE, Sanchez A et al (2018) Profile of BAFF and its receptors\u2019 expression in lupus nephritis is associated with pathological classes. Lupus 27(5):708\u2013715. https:\/\/doi.org\/10.1177\/0961203317739132","journal-title":"Lupus"},{"key":"7266_CR31","doi-asserted-by":"publisher","first-page":"954292","DOI":"10.1155\/2013\/954292","volume":"2013","author":"CY Sun","year":"2013","unstructured":"Sun CY, Shen Y, Chen XW, Yan YC, Wu FX, Dai M et al (2013) The characteristics and significance of locally infiltrating B cells in lupus nephritis and their association with local BAFF expression. Int J Rheumatol 2013:954292. https:\/\/doi.org\/10.1155\/2013\/954292","journal-title":"Int J Rheumatol"},{"issue":"5","key":"7266_CR32","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1002\/art.33458","volume":"64","author":"CO Jacob","year":"2012","unstructured":"Jacob CO, Guo S, Jacob N, Pawar RD, Putterman C, Quinn WJ 3rd et al (2012) Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice. Arthritis Rheum 64(5):1610\u20131619. https:\/\/doi.org\/10.1002\/art.33458","journal-title":"Arthritis Rheum"},{"issue":"2","key":"7266_CR33","doi-asserted-by":"publisher","first-page":"e31837","DOI":"10.1371\/journal.pone.0031837","volume":"7","author":"B Huard","year":"2012","unstructured":"Huard B, Tran NL, Benkhoucha M, Manzin-Lorenzi C, Santiago-Raber ML (2012) Selective APRIL blockade delays systemic lupus erythematosus in mouse. PLoS One 7(2):e31837. https:\/\/doi.org\/10.1371\/journal.pone.0031837","journal-title":"PLoS One"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07266-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-07266-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-07266-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T13:40:21Z","timestamp":1736775621000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-07266-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["7266"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-07266-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"assertion":[{"value":"26 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Permission for conduct of the human study was obtained from the ethical committee of the first affiliated hospital of USTC and was performed in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Patient and\/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient and public involvement"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}